导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 3.66% | 1349/4773 |
| 近一周 | -2.61% | 2671/5462 |
| 近一月 | -3.92% | 2078/5421 |
| 近一季 | -4.94% | 1733/5209 |
| 近半年 | -5.16% | 2764/4920 |
| 近一年 | 9.35% | 1102/4366 |
| 近两年 | 79.40% | 817/2954 |
| 近三年 | 50.02% | 537/2253 |
| 成立以来 | 103.24% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
1.47% 1263/4961 |
8.80% 2540/5312 |
- - |
- - |
| 2025 | 35.13% 1002/4813 |
3.52% 1073/3635 |
3.80% 945/4076 |
22.80% 1611/4524 |
2.41% 962/4813 |
| 2024 | 11.14% 1343/3463 |
-0.57% 1126/2808 |
-2.70% 1233/3014 |
13.60% 2151/3129 |
1.12% 1117/3463 |
| 2023 | -3.28% 633/2656 |
5.90% 745/2280 |
-3.15% 747/2385 |
-1.90% 596/2515 |
-3.87% 808/2655 |
| 2022 | -14.49% 372/2207 |
-13.14% 703/1919 |
5.91% 809/2016 |
-9.74% 305/2113 |
2.99% 790/2208 |
| 2021 | 16.01% 286/1822 |
-0.16% 336/1255 |
7.06% 704/1330 |
5.73% 259/1466 |
2.65% 545/1822 |
| 2020 | 32.33% 488/1250 |
-2.84% 275/1028 |
20.68% 264/1067 |
9.29% 660/1164 |
3.26% 927/1184 |
| 2019 | 27.74% 533/1092 |
27.93% 330/754 |
-6.83% 527/804 |
1.40% 405/850 |
5.69% 689/918 |
| 2018 | -31.00% 486/834 |
- - |
- - |
- - |
-11.73% 343/691 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 招商中证500指数A VS. 长安沪深300非周期A(740101) |